Ignite Creation Date:
2025-12-24 @ 1:15 PM
Ignite Modification Date:
2026-05-15 @ 8:07 PM
Study NCT ID:
NCT05361395
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-25
First Post:
2022-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor:
Organization: